IP Library › Granted Patent US 12661316
Granted Patent B2
US 12661316 · App. 18/117,328 · Granted Jun 23, 2026

Creatine and/or creatinine compositions and related methods

Inventors: Ronald Kramer (Signal Hill, CA); Alexandros Nikolaidis (Nea Kallikratia, GR)
Assignee: ThermoLife International, LLC
A61K9/08A61K31/4168A61K47/02A61P21/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12661316
App. No.
18/117,328
Granted
Jun 23, 2026
Kind
B2
Abstract

The disclosure is directed to methods related to creatinine, for example, a method for its safe administration to a human.

Claims (18)

1 . A method of safely administering creatinine to a subject in need thereof, said method comprising co-administering an effective amount of creatinine with an effective amount of creatine and an effective amount of a nitrate (NO3-) source selected from sodium nitrate, potassium nitrate, or creatine nitrate to the subject.

2 . The method of claim 1 , wherein the effective amount of creatinine is at least 500 mg.

3 . The method of claim 2 , wherein the effective amount of creatine is at least 500 mg and the effective amount of nitrate (NO3-) is at least 50 mg.

4 . The method of claim 2 , wherein the effective amount of nitrate (NO3 − ) is between 50 mg and 1200 mg nitrate (NO 3 − ).

5 . The method of claim 2 , wherein the effective amount of nitrate (NO 3 − ) is between 50 mg and 1500 mg nitrate (NO 3 − ).

6 . The method of claim 2 , wherein the effective amount of nitrate (NO 3 − ) is between 60 mg and 1500 mg nitrate (NO 3 − ).

7 . The method of claim 2 , wherein the effective amount of nitrate (NO 3 − ) is between 60 mg and 1200 mg nitrate (NO 3 − ).

8 . The method of claim 1 , wherein the effective amount of creatinine is at least 1000 mg.

9 . The method of claim 8 , wherein the effective amount of creatine is at least 1000 mg and the effective amount of nitrate (NO3-) is at least 100 mg.

10 . The method of claim 1 , wherein the effective amount of creatinine is at least 2 g.

11 . The method of claim 10 , wherein the effective amount of creatine is at least 2 g and the effective amount of nitrate (NO3-) is at least 500 mg.

12 . The method of claim 1 , wherein the effective amount of creatinine is at least 3 g.

13 . The method of claim 12 , wherein the effective amount of creatine is at least 5 g and the effective amount of nitrate (NO3-) is at least 1000 mg.

14 . The method of claim 12 , comprising 3 g of creatinine and 3 g of creatine nitrate.

15 . The method of claim 12 , comprising 5 g of creatinine and 5 g of creatine nitrate.

16 . The method of claim 1 , wherein the molar ratio of the amount of nitrate (NO 3 − ) to the amount of creatinine is one of between about 20:1 and about 1:9, between about 10:1 and about 1:1, between about 3:1 and about 1:3, and between about 2:1 and about 1:4.

17 . The method of claim 1 , wherein the co-administration of creatinine, creatine, and nitrate (NO3-) causes no clinically significant elevation in liver enzymes or clinically significant reduction in estimated glomerular filtration rate.

18 . The method of claim 1 , wherein the effective amount of creatinine can be administered safely for a period of 5 days or longer.